SOLIGENIX, INC. — fact timeline

SOLIGENIX, INC. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“November 18, 2025, the Company received a letter from Nasdaq confirming that the Company had regained compliance with the Shareholders’ Equity Requirement and that the matter is now closed. ​”

SOLIGENIX, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“August 15, 2025, Soligenix, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). In the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, the Company reported stockholders’ equity of $1,828,951”

SOLIGENIX, INC. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at cash fee of six and one-half percent (6.5%) of the gross proceeds of the Offering (effective 2024-04-17).

“A.G.P./Alliance Global Partners acted as the sole placement agent (the “Placement Agent”) on a “reasonable best efforts” basis in connection with the Offering pursuant to a Placement Agency Agreement, dated April 17, 2024, by and between the Company and the Placement Agent (the “Placement Agency Agreement”).”

SOLIGENIX, INC. entered into Securities Purchase Agreement with certain investors valued at aggregate gross proceeds from the Offering are approximately $4.75 million (effective 2024-04-17).

“On April 17, 2024, Soligenix, Inc., a Delaware corporation (the “Company”) entered into a Securities Purchase Agreement with certain investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a public offering (the “Offering”) (i) 3,275,000 shares of the Company’s common stock, (ii) pre-funded warrants to purchase 8,600,000 shares of the Company’s common stock and (iii) common warrants to purchase 11,875,000 shares of the Company’s common stock.”

SOLIGENIX, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“December 21, 2023, the Company received written notice (the “Notice”) from Nasdaq stating that the Company has not complied with the Minimum Bid Price Rule and is not eligible for a second 180 day period because the Company does not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for The Nasdaq Capital Market. In that regard, the Company’s Form 10-Q for the quarter ended September 30, 2023 reported stockholders’ equity of $4,221,155. As a result, the Notice indicated that the Company’s common stock would be suspended from trading on Nasdaq unless the Company”

SOLIGENIX, INC. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-12-15 meeting.

“Proposal Three Ratification of the Appointment of Independent Registered Public Accounting Firm: The proposal to ratify the appointment of Cherry Bekaert LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023 was approved by votes as follows: For Against Abstain 4,439,358 188,624 887,512”

SOLIGENIX, INC. shareholders approved Non-binding advisory vote on executive compensation at the 2023-12-15 meeting.

“Proposal Two Non-binding advisory vote on executive compensation: The proposal to approve, by a non-binding advisory vote, the compensation of the Company’s named executive officers as disclosed in the Company’s 2023 proxy statement was approved, and the votes were as follows: For Against Abstain 2,315,274 707,529 889,790”